DNA logo

Ginkgo Bioworks Holdings (DNA)

Profile

Full Name

Ginkgo Bioworks Holdings, Inc.

Ticker Symbol

DNA

Exchange

NYSE

Sector

Healthcare

Industry

Biotechnology

Country

United States

IPO

April 19, 2021

Indexes

Not included

Website

http://www.ginkgo.bio

Employees

834

Key Details

Price

$7.87(+7.81%)

Market cap

$456.72M(Small cap)

Last Dividend

-

TTM Dividend yield

-

Annual revenue

$227.04M(-9.71% YoY)

Annual EPS

-$10.54(+42.62% YoY)

PE ratio

-

Next earnings date

May 9, 2025

Next ex-dividend date

N/A

Next split date

N/A

Price

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Current Price

$7.87
DNA price is $7.87

30-Day Relative Volume

1.94
DNA 30-day relative volume is 1.94

Price Performance

Price Today change

+7.81%
DNA price is up +7.81% today

Price YTD change

-19.86%
DNA price is down -19.86% since January 1st

Price 1-year change

-81.26%
DNA price is down -81.26% year-on-year

Price 3-year change

-94.13%
DNA price is down -94.13% over the past 3 years

Price Range

Price All-time high

$596.80
DNA price is currently -98.68% below its historical high of $596.80

Price 3-year low

$0.26
DNA price is currently +2974.22% above its 3-year low

Capitalization

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Market cap

Market cap

$456.72M
DNA market capitalization is $456.72 million

Market cap 3-year change

-92.1%
DNA market capitalization is down -92.1% over the past 3 years

Market cap All-time high

$788.86B
DNA market capitalization is currently -99.94% below its historical high of $788.86 billion

Market cap sector rank

68.69%
DNA market capitalization is higher than 68.69% of companies in Healthcare sector

Shares Outstanding

Shares Outstanding 1-Year Change

+6.87%
DNA shares outstanding is up +6.87% year-on-year

Shares Outstanding 3-Year Change

+42.61%
DNA shares outstanding is up +42.61% over the past 3 years

Technical Indicators

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Beta

2.09
DNA beta is 2.09

200-day SMA

$9.50
DNA price is currently -17.17% below its 200-day simple moving average

50-day SMA

$9.21
DNA price is currently -14.52% below its 50-day simple moving average

RSI

51.15
DNA 14-day relative strength index is 51.15

Volume

1.94
DNA 30-day relative volume is 1.94

ATR

$0.86
DNA average true range is $0.86

10-day Historical Volatility

152.72%
DNA 10-day historical volatility is 152.72%

Dividend

Income Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Revenue

$227.04M
DNA annual revenue is $227.04 million

Revenue Analysts estimate

$174.32M
DNA annual revenue is currently +30.24% higher than the consensus analysts' forecast

Revenue 1-year change

-9.71%
DNA annual revenue is down -9.71% year-on-year

Revenue Sector rank

65.85%
DNA annual revenue is higher than 65.85% of companies in Healthcare sector

EPS

EPS

-$10.54
DNA annual earnings per share is -$10.54

EPS Analysts estimate

-
DNA annual earnings per share consensus analysts' forecast is unknown

EPS 1-year change

+42.62%
DNA annual earnings per share is up +42.62% year-on-year

EPS Sector rank

11.56%
DNA annual earnings per share is higher than 11.56% of companies in Healthcare sector

Profit

Gross profit

$182.50M
DNA annual gross profit is $182.50 million

Gross margin

80.38%
DNA annual gross profit margin is 80.38%

Operating profit

-$487.73M
DNA annual operating income is -$487.73 million

Operating margin

-214.82%
DNA annual operating profit margin is -214.82%

Net income

-$547.03M
DNA annual net profit is -$547.03 million

Net margin

-240.94%
DNA annual net profit margin is -240.94%

Expenses

Total expenses

$714.77M
DNA annual total expenses is $714.77 million

Operating expenses

$670.22M
DNA annual total operating expenses is $670.22 million

Cost of goods sold

$44.55M
DNA annual cost of goods sold is $44.55 million

Selling, general & administrative expenses

$246.16M
DNA annual SGA is $246.16 million

Depreciation and amortization

$63.02M
DNA annual depreciation & amortization is $63.02 million

Interest expense

$94.00K
DNA annual interest expense is $94.00 thousand

Income tax

-$479.00K
DNA annual income tax is -$479.00 thousand

EBIT & EBITDA

EBIT

-$547.41M
DNA annual earnings before interest & taxes is -$547.41 million

EBITDA

-$484.39M
DNA annual EBITDA is -$484.39 million

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Total assets

$1.38B
DNA annual total assets is $1.38 billion

Non current assets

$774.71M
DNA annual long term assets is $774.71 million

Current assets

$602.74M
DNA annual total current assets is $602.74 million

Cash and cash equivalents

$561.57M
DNA annual cash & cash equivalents is $561.57 million

Accounts receivable

$21.86M
DNA annual accounts receivable is $21.86 million

Inventory

-
DNA annual inventory value is unknown

Liabilities

Total liabilities

$661.39M
DNA annual total liabilities is $661.39 million

Long term liabilities

$554.13M
DNA annual total long term liabilities is $554.13 million

Current liabilities

$107.27M
DNA annual total current liabilities is $107.27 million

Accounts payable

$14.17M
DNA annual accounts payable is $14.17 million

Debt

Total debt

$467.73M
DNA annual total debt is $467.73 million

Total debt 1-year change

+95.45%
DNA annual total debt is up +95.45% year-on-year

Long term debt

$438.77M
DNA annual long term debt is $438.77 million

Short term debt

$28.96M
DNA annual short term debt is $28.96 million

Equity & Capital

Shareholders equity

$716.06M
DNA annual stockholders equity is $716.06 million

Book value

$716.06M
DNA annual book value is $716.06 million

Retained earnings

-$5.84B
DNA annual retained earnings is -$5.84 billion

Working capital

$495.48M
DNA annual working capital is $495.48 million

Cash Flow Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Cash from operations

-$319.58M
DNA annual cash flow from operations is -$319.58 million

Cash from operations 1-year change

-8.15%
DNA annual cash flow from operations is down -8.15% year-on-year

Cash from investing

-$62.24M
DNA annual cash flow from investing activities is -$62.24 million

Cash from investing 1-year change

+22.87%
DNA annual cash flow from investing activities is up +22.87% year-on-year

Cash from financing

-$1.74M
DNA annual cash flow from financing activities is -$1.74 million

Cash from financing 1-year change

+45.93%
DNA annual cash flow from financing activities is up +45.93% year-on-year

CAPEX

CAPEX

$62.54M
DNA annual capital expenditures is $62.54 million

CAPEX 1-year change

+53.28%
DNA annual capital expenditures is up +53.28% year-on-year

Free Cash Flow

Free cash flow

-$382.13M
DNA annual free cash flow is -$382.13 million

Free cash flow 1-year change

-13.63%
DNA annual free cash flow is down -13.63% year-on-year

Profitability Ratios

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Margins

Gross margin

80.38%
DNA annual gross profit margin is 80.38%

Operating margin

-214.82%
DNA annual operating profit margin is -214.82%

Net margin

-240.94%
DNA annual net profit margin is -240.94%

ROA & ROE

ROA

-35.96%
DNA annual return on assets is -35.96%

ROE

-60.34%
DNA annual return on equity is -60.34%

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE ratio

-
DNA price to earnings ratio value is unknown

PE ratio Sector rank

-
DNA price to earnings ratio is unknown

PB Ratio

PB ratio

0.64
DNA price to book ratio is 0.64

PB ratio Sector rank

35.69%
DNA price to book ratio is higher than 35.69% of companies in Healthcare sector

PS Ratio

PS ratio

2.01
DNA price to sales ratio is 2.01

PS ratio Sector rank

43.72%
DNA price to sales ratio is higher than 43.72% of companies in Healthcare sector

Enterprise value

Enterprise value

$362.88M
DNA enterprise value is $362.88 million

Enterprise value Sector rank

65.79%
DNA enterprise value is higher than 65.79% of companies in Healthcare sector

EV/EBITDA

EV/EBITDA

-0.75
DNA EV/EBITDA is -0.75

EV/EBITDA Sector rank

46.61%
DNA EV/EBITDA is higher than 46.61% of companies in Healthcare sector

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Current ratio

5.62
DNA annual current ratio is 5.62

Quick ratio

-
DNA annual quick ratio value is unknown

Leverage

Debt to equity

0.00
DNA annual debt to equity ratio is 0.00

Interest coverage ratio

-5823.55
DNA annual interest coverage ratio is -5823.55

Risk & Stability

Piotroski F-Score

2
DNA piotroski f-score is 2

Altman Z-Score

-6.23
DNA altman z-score is -6.23

Analyst ratings

Recent major analysts updates

Sep 20, 24 TD Cowen
Buy
Aug 23, 24 BTIG
Sell
Jul 9, 24 Goldman Sachs
Sell
Jun 26, 24 BTIG
Sell
May 15, 24 Morgan Stanley
Equal-Weight
May 15, 24 BTIG
Sell
May 10, 24 William Blair
Underperform
Mar 1, 24 TD Cowen
Outperform
Jan 23, 24 Goldman Sachs
Sell
Jan 22, 24 Goldman Sachs
Sell

Institutional Ownership

Similar stocks

SIGA logo
SIGA Technologies (SIGA)
SAGE logo
Sage Therapeutics (SAGE)
LAB logo
Standard BioTools (LAB)
TBPH logo
Theravance Biopharma (TBPH)
URGN logo
UroGen Pharma (URGN)
MDRX logo
Veradigm (MDRX)
Beta Bionics (BBNX)
PACB logo
Pacific Biosciences of California (PACB)
TMCI logo
Treace Medical Concepts (TMCI)
  • What is the ticker symbol for Ginkgo Bioworks Holdings?
  • Does Ginkgo Bioworks Holdings pay dividends?
  • What sector is Ginkgo Bioworks Holdings in?
  • What industry is Ginkgo Bioworks Holdings in?
  • What country is Ginkgo Bioworks Holdings based in?
  • When did Ginkgo Bioworks Holdings go public?
  • Is Ginkgo Bioworks Holdings in the S&P 500?
  • Is Ginkgo Bioworks Holdings in the NASDAQ 100?
  • Is Ginkgo Bioworks Holdings in the Dow Jones?
  • When was Ginkgo Bioworks Holdings's last earnings report?
  • When does Ginkgo Bioworks Holdings report earnings?
  • Should I buy Ginkgo Bioworks Holdings stock now?

What is the ticker symbol for Ginkgo Bioworks Holdings?

The ticker symbol for Ginkgo Bioworks Holdings is NYSE:DNA

Does Ginkgo Bioworks Holdings pay dividends?

No, Ginkgo Bioworks Holdings does not pay dividends

What sector is Ginkgo Bioworks Holdings in?

Ginkgo Bioworks Holdings is in the Healthcare sector

What industry is Ginkgo Bioworks Holdings in?

Ginkgo Bioworks Holdings is in the Biotechnology industry

What country is Ginkgo Bioworks Holdings based in?

Ginkgo Bioworks Holdings is headquartered in United States

When did Ginkgo Bioworks Holdings go public?

Ginkgo Bioworks Holdings's initial public offering (IPO) was on April 19, 2021

Is Ginkgo Bioworks Holdings in the S&P 500?

No, Ginkgo Bioworks Holdings is not included in the S&P 500 index

Is Ginkgo Bioworks Holdings in the NASDAQ 100?

No, Ginkgo Bioworks Holdings is not included in the NASDAQ 100 index

Is Ginkgo Bioworks Holdings in the Dow Jones?

No, Ginkgo Bioworks Holdings is not included in the Dow Jones index

When was Ginkgo Bioworks Holdings's last earnings report?

Ginkgo Bioworks Holdings's most recent earnings report was on Feb 25, 2025

When does Ginkgo Bioworks Holdings report earnings?

The next expected earnings date for Ginkgo Bioworks Holdings is May 9, 2025

Should I buy Ginkgo Bioworks Holdings stock now?

As of today, analysts generally recommend a 'Hold' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions
On this page